venetoclax

Org: The University of Texas MD Anderson Cancer Center, Maria Skłodowska-Curie National Research Institute of Oncology, General University Hospital in Prague, Charles University Hospital and Faculty of Medicine, Wrocław Medical University,

Abstract

A retrospective comparison of abbreviated course “7+7” vs standard hypomethylating agent plus venetoclax doublets in older/unfit patients with newly diagnosed acute myeloid leukemia.

Org: The University of Texas MD Anderson Cancer Center, Department of Leukemia, Centre Hospitalier Régional Universitaire de Nîmes, Hopital Cochin, Groupement des Hôpitaux de l'Institut Catholique de Lille,

Abstract

Multi-drug algorithm to accurately predict best first-line treatments in newly-diagnosed acute myeloid leukemia (AML).

Org: Macclesfield, United Kingdom, Princess Margaret Hospital, University Health Network,

Abstract

CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naïve (TN) CLL.

Org: Lymphoma and Myeloma Research Amsterdam, St. James's Hospital, BeiGene International GmbH, Department of Haematological Medicine,

Abstract

A prospective study of all-trans retinoic acid plus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia.

Org: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Hygeia Suzhou Yongding Hospital, National Regional Medical Center,

Abstract

A phase II study of venetoclax (VEN) in combination with 10-day decitabine (DEC) in older/unfit pts with newly diagnosed (ND) or pts with relapsed/refractory (R/R) acute myeloid leukemia (AML), or high-risk myelodysplastic syndrome (HR-MDS).

Org: Bellaire,

Abstract

FLAG-IDA + venetoclax in newly diagnosed (ND) or relapsed/refractory (RR) AML.

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Leukemia,

Abstract

Real world incidence, prevention, and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax in the inpatient and outpatient settings.

Org: St. Luke's Roosevelt,

Abstract

A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine for patients with newly diagnosed CD123-positive acute myeloid leukemia.

Org: Hospital Universitari i Politecnic La Fe de Valencia, Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Medical Clinic and Policlinic, Hematology and Cellular Therapy, University Hospital Leipzig, Weatherall Institute of Molecular Medicine, MRC Molecular Hematology Unit, University of Oxford, University Hospital Muenster,

Abstract

A phase 1 single-arm, open-label study of emavusertib (CA-4948) in combination with azacitidine and venetoclax in patients (pts) with acute myeloid leukemia (AML) in complete response (CR) with measurable residual disease (MRD).

Org: MD Anderson Cancer Center Madrid, Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS, Universitätsklinikum Jena, Technische Universität Dresden, Curis Inc,

Abstract

Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort.

Org: Georgia Cancer Center, Augusta University, Augusta University/University of Georgia Medical Partnership, School of Medicine, Zhejiang University, Hangzhou, China, University of California, Davis Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL,

Abstract

BELLWAVE-010: A phase 3 study of nemtabrutinib plus venetoclax versus venetoclax plus rituximab (VR) in previously treated patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Org: Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele,

Abstract

Outcomes of blast-phase MPN and JAK2, MPL, and CALR mutated de novo AML: A propensity score-adjusted cohort study.

Org: Cleveland Clinic Foundation, Cleveland Clinic Taussig Cancer Center, University of Minnesota Medical Center,

Abstract

BGB-11417-203: An ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia.

Org: Lymphoma Research Group, School of Clinical Sciences at Monash Health, Monash University, Hattiesburg Clinic, Genesis Care North Shore, Affiliated Zhongshan Hospital of Fudan University, BeiGene (Beijing) Co, Ltd,

Abstract

Randomized phase II/III study of R-CHOP +/- venetoclax in previously untreated MYC/BCL2 double expressor diffuse large B cell lymphoma (DLBCL): Alliance A051701.

Org: Massachusetts General Hospital, Alliance Statistics and Data Management Center, Mayo Clinic Rochester, Rochester, MN, Mayo Clinic, National Cancer Institute, Vilnius, Lithuania,

Abstract

Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the phase 2 CAPTIVATE study.

Org: ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, Ministry of Health, Kogarah, NSW, Australia, AbbVie, North Chicago, IL, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy,

Abstract

Synergistic effects of RPT1G, a first-in-class small molecule NAMPT inhibitor, with venetoclax and olaparib in hematological malignancies.

Org: Remedy Plan Therapeutics, UCSF Helen Diller Family Comp Cancer Ctr,

Abstract

Interim safety and efficacy of BP1001 in a phase II acute myeloid leukemia (AML) study.

Org: NYU Langone Health, New York, NY, Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas, Kansas City, KS, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Augusta University, Augusta, GA, Bio-Path Holdings, Inc., Bellaire, TX,

Clinical trial

Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Status: Recruiting, Estimated PCD: 2024-07-15

Clinical trial

An Open-label, Multicenter, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Status: Recruiting, Estimated PCD: 2027-09-20

Clinical trial

A Multicenter, Prospective, Randomized Controlled Clinical Study Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in the Treatment of Adult Newly Diagnosed Early Precursor T-cell Acute Lymphoblastic Leukemia (ETP-ALL)

Status: Recruiting, Estimated PCD: 2026-03-31

Clinical trial

Phase 1/2 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

Status: Recruiting, Estimated PCD: 2025-03-10

Clinical trial

A Phase Ib/II Open Label Dose Confirmation, Proof of Concept Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Unfit Adult AML Participants Who Responded Sub-optimally to First-line Venetoclax Plus Azacitidine Treatment and in Participants With Newly Diagnosed Unfit AML Presenting With High-risk Clinical Features

Status: Active (not recruiting), Estimated PCD: 2024-05-28

Abstract

Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome.

Org: Niguarda Cancer Center, Laboratory of Experimental Hematology, Clinic of Hematology, Ente Ospedaliero Cantonale, Universita’ della Svizzera italiana,

Abstract

Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance).

Org: Alliance Statistics and Data Management Center, Alliance Protocol Operations Office, Illinois CancerCare, Mayo Clinic, Trinity Health Saint Joseph Mercy Hospital,

Abstract

Association of intensive chemotherapy with the rate of pathogenic driver mutation clearance in acute myeloid leukemia.

Org: Ochsner Clinic Foundation, University of Queensland, Ochsner Health System,

Abstract

Implications for acute myeloid leukemia (AML) treatment and care during the COVID-19 pandemic: A Connect Myeloid Registry study.

Org: Fred Hutchinson Cancer Research Center, Sylvester Comprehensive Cancer Center, Miami, FL, University of Miami Health System, University of Texas MD Anderson Cancer Center, Northshore University Healthsystem,

Abstract

SAVE (Safe Accelerated Venetoclax Escalation): Initial results of a prospective, phase Ib study of venetoclax with an accelerated dose ramp-up in patients with CLL.

Org: Dana-Farber Cancer Institute, Department of Data Sciences, DFCI/PCC Fellowship Program - Attendings,

Abstract

Efficacy and safety of venetoclax in combination with cytarabine and azacitidine (VAA) in relapsed/refractory acute myeloid leukemia: An open-label, single-arm, phase II study.

Org: The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, College of Medicine, University of the Philippines - Manila, Zhejiang University, Hangzhou, China, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China,

Abstract

Outcomes of 10-day decitabine with venetoclax for AML.

Org: Medical University of South Carolina Hollings Cancer Center,

Abstract

Association of pharmacist interventions with adherence upon targeted anticancer oral therapy initiation.

Org: VA Salt Lake City Health Care, AbbVie Inc., North Chicago, IL, Hunstman Cancer Institute at the University of Utah,

Abstract

Analysis of racial disparities accounting for treatment received in chronic lymphocytic leukemia: A real-world cohort analysis.

Org: Medical Affairs, AstraZeneca Pharmaceuticals, Global Medical Affairs, AstraZeneca Pharmaceuticals, Mount Sinai Comprehensive Cancer Center,

Abstract

Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study.

Org: Wilmot Cancer Institute, University of Rochester Medical Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, City of Hope Comprehensive Cancer Center, University of Texas MD Anderson Cancer Center,

Abstract

The characteristics of metabolic related pathways under different anoikis activities revealed by pan-cancer analyses.

Org: Hangzhou Repugene Technology Co., Ltd., Hangzhou Repugene Technology Co,.Ltd,

Abstract

Addition of venetoclax to FLAI induction chemotherapy (VFLAI) improves survival in patients with intermediate and high-risk AML vs FLAI and 3+7: A GIMEMA Italian Cooperative analysis.

Org: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST (IRCCS), Fondazione Gimema, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori “Dino Amadori” (IRST) IRCCS, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, IRCCS AOU San Martino,

Abstract

A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine or magrolimab for patients with CD123-positive acute myeloid leukemia (AML).

Org: ImmunoGen, University of Texas MD Anderson Cancer Center, Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST) IRCCS, Meldola, Italy, Roswell Park Comprehensive Cancer Center, Fred Hutchinson Cancer Research Center,

Abstract

Predictors of early port infection in adult patients with acute myeloid leukemia.

Org: University of Alabama at Birmingham Department of Hematology, Birmingham, AL, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, Surgical Oncology, Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, The University of Alabama at Birmingham/O'Neal Comprehensive Cancer Center,

Abstract

Phase 1 study of ziftomenib (KO-539) in combination with venetoclax or venetoclax/azacitidine or standard induction cytarabine/daunorubicin (7+3) chemotherapy for the treatment of patients with acute myeloid leukemia.

Org: Kura Oncology, Massachusetts General Hospital, Harvard Medical School, Department of Leukemia, Roswell Park Comprehensive Cancer Center,

Abstract

Results from a phase (Ph) 1 clinical study of the all-oral regimen of CC-486 and venetoclax for acute myeloid leukemia (AML).

Org: University of Colorado, Aurora, CO,

Abstract

Myeloablative fractionated busulfan-based conditioning regimen in patients with AML and MDS: Results of a randomized clinical trial comparing 2 fractionation schedules.

Org: University of Texas MD Anderson Cancer Center, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Department of Stem Cell Transplantation & Cellular Therapy,

Abstract

Superior outcomes after allogeneic stem cell transplantation (SCT) among patients (Pts) ≥ 60 years (yrs) treated with cladribine (CLAD), low dose cytarabine (LDAC) plus venetoclax (Ven) for newly diagnosed acute myeloid leukemia (AML).

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation & Cellular Therapy,

Abstract

Real-world (RW) use of venetoclax (VEN) in patients (pts) with acute myeloid leukemia (AML) in a US RWE database (COTA).

Org: Novartis Pharma AG, Novartis Oncology, Genesis Research, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Yale School of Medicine,

Abstract

A phase 1/2 dose escalation study of the BCL-2 inhibitor ZN-d5 and the WEE1 inhibitor azenosertib (ZN-c3) in patients (Pts) with acute myeloid leukemia (AML).

Org: Zentalis Pharmaceuticals, Memorial Sloan Kettering Cancer Center, Medical College of Wisconsin, The James Cancer Hospital and Solove Research Institute, University of Texas M.D. Anderson Cancer Center,

Abstract

Preliminary results of a phase 1, first-in-human study of INA03, an anti-CD71 antibody-drug conjugate, in patients with relapsed or refractory (R/R) acute leukemias.

Org: Institut Paoli-Calmettes, Marseille, France, Aix-Marseille University CHU Timone, Marseille, France, Institut Universitaire du Cancer Toulouse, Toulouse, France,

Abstract

A study of frontline therapy in adults >80 years with chronic lymphocytic leukemia (CLL).

Org: Mayo Clinic, Division of Clinical Trials and Biostatistics, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Department of Laboratory and Oncology, Mayo Clinic, Rochester, MN, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN,

Abstract

Sequential salvage chemotherapy and lintuzumab-Ac225 results in deep responses and prolonged survival in adverse risk relapsed/refractory AML and in AML patients that received prior venetoclax therapy.

Org: Medical College of Wisconsin, Actinium Pharmaceuticals,

Abstract

Venetoclax pharmacokinetics in subjects with end-stage renal disease undergoing hemodialysis.

Org: AbbVie Inc., North Chicago, IL, Genentech, AbbVie, Orlando Clinical Research Center,

Abstract

BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma.

Org: Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center, Faculty Hospital Hradec Kralove,

Abstract

Safety of concurrent use of radiotherapy for second primary malignancy (SPM) in patients with chronic lymphocytic leukemia (CLL) receiving novel agent therapy.

Org: Mayo Clinic, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Division of Clinical Trials and Biostatistics,

Abstract

Disparities in uptake of novel therapies for acute myeloid leukemia.

Org: Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, Dana-Farber Cancer Institute,

Abstract

Incidence of cardiac events in patients with MDS or AML receiving azacitidine or decitabine within a large community health system.

Org: University of Illinois Chicago, Advocate Aurora Health,

Abstract

Novel RNA epigenetics-driven technologies for rapid prediction of cancer drug resistance.

Org: University of Chicago, Chicago, IL, Rush University Medical Center,

Abstract

Incidence of drug-induced myelosuppression and associated adverse events (AEs), quality of life (QOL), and medical resource use (MRU) in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Org: Certara Evidence & Access, Gilead Sciences, Inc., Gilead Sciences Europe Ltd,

Abstract

Treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: A real-world observational chart review study.

Org: RTI Health Solutions, Pfizer Inc., London, United Kingdom,

Abstract

Synergistic activity of JAK2 and BCL-2 inhibition against B-cell acute lymphoblastic leukemia.

Org: University of Wisconsin School of Medicine and Public Health, Madison, WI,

Abstract

A randomized, open-label study of the efficacy and safety of galinpepimut-S (GPS) maintenance monotherapy compared to investigator's choice of best available therapy (BAT) in patients with acute myeloid leukemia (AML) who have achieved complete remission (CR) after second-line salvage therapy.

Org: University of Alabama at Birmingham Department of Hematology, Birmingham, AL, Bon Secours St Francis Health System, University General Hospital Attikon, University Hospitals Seidman Cancer Center, CHU Angers,

Abstract

Olutasidenib in post-venetoclax patients with mIDH1 AML.

Org: Georgia Cancer Center, Augusta University, Medical College of Georgia at Augusta University, Augusta, GA, Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine at UCLA,

Abstract

Gilteritinib plus azacitidine and venetoclax for FLT3-ITD mutated relapsed/refractory acute myeloid leukemia.

Org: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, First Affiliated Hospital of Wannan Medical College, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China, Shulan (Hangzhou) Hospital, Zhejiang Shuren University Shulan International Medical College,

Abstract

Gilteritinib or venetoclax in relapsed or refractory FLT3mut acute myeloid leukemia.

Org: VCU School of Medicine, VCU Massey Cancer Center, VCU Department of Internal Medicine, VCU Department of Biostatistics,

Abstract

IDH inhibitors or chemotherapy in relapsed or refractory IDHmut acute myeloid leukemia.

Org: VCU School of Medicine, VCU Massey Cancer Center, VCU Department of Internal Medicine, VCU Department of Biostatistics,

Abstract

Real-world (RW) treatment (tx) patterns of patients (pts) with higher-risk myelodysplastic syndrome (MDS) in a US RWE database (COTA).

Org: Novartis Pharma AG, Basel, Switzerland, Novartis Oncology,

Abstract

Association of venetoclax-based therapy with increased survival in multiple myeloma (MM) harboring t(11;14): A single-center experience.

Org: H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine,

Abstract

Outcomes of different therapies in acute myeloid leukemia patients with core-binding factor.

Abstract

Venetoclax with decitabine or azacitidine in previously untreated TP53mut acute myeloid leukemia.

Org: VCU Massey Cancer Center, VCU School of Medicine, VCU Department of Internal Medicine, Virginia Commonwealth University School of Medicine, VCU Department of Biostatistics,

Abstract

Predictors of survival outcomes in patients with MECOM EVI1 rearrangement aberrations in AML or MDS.

Org: Mayo Clinic Arizona, Phoenix, AZ, Mayo Clinic, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Mayo Clinic Jacksonville, Division of Hematopathology, Mayo Clinic, Rochester, MN,

Abstract

The impact of secondary-type mutations in newly diagnosed acute myeloid leukemia treated with venetoclax and decitabine or azacitidine.

Org: VCU School of Medicine, VCU Massey Cancer Center, VCU Department of Internal Medicine, Virginia Commonwealth University School of Medicine, VCU Department of Biostatistics,

Abstract

Clinical outcomes of core binding factor acute myeloid leukemia in the modern era.

Org: Virginia Commonwealth University School of Medicine, VCU Massey Cancer Center, VCU School of Medicine, VCU Department of Internal Medicine, VCU Department of Biostatistics,

Abstract

Real-world evidence study of treatment patterns and outcomes following covalent BTKi discontinuation in a contemporary cohort of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients.

Org: Dana-Farber Cancer Institute, Boston Pharmaceuticals, MaaT Pharma, Analysis Group, Inc., Inc.,

Abstract

A phase 2 study of the combination of decitabine (DAC), venetoclax (VEN), and ponatinib in patients (Pts) with chronic myeloid leukemia (CML) in accelerated phase (AP)/myeloid blast phase (MBP) or Philadelphia-chromosome positive (Ph+) acute myeloid leukemia (AML).

Org: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas MD Anderson Cancer Center, University of Texas at MD Anderson Cancer Center,

Abstract

A real-world evaluation of treatment (Tx) patterns and outcomes of acute myeloid leukemia (AML) induction therapies in the community setting.

Org: VCU Massey Cancer Center, Cardinal Health, Bristol Myers Squibb, Cardinal Health Specialty Solutions, Hematology Oncology Associates of CNY,

Abstract

Clinical outcomes of patients with multiple myeloma following disease progression after BCMA-targeted CAR T-cell therapy.

Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, UT Health Sciences Center at Houston, University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,

Abstract

FLAG-IDA or venetoclax in previously treated TP53mut acute myeloid leukemia.

Org: VCU Department of Internal Medicine, VCU Massey Cancer Center, VCU School of Medicine, Virginia Commonwealth University School of Medicine, VCU Department of Biostatistics,

Abstract

Phase 1b OMNIVERSE trial: Safety and tolerability of oral azacitidine (Oral-AZA) in combination with venetoclax (VEN) for treatment of acute myeloid leukemia.

Org: Bristol Myers Squibb, MD Anderson Cancer Center,

Abstract

Mini-hyper-CVD with venetoclax (Ven) for patients with relapsed/refractory (R/R) Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL): A phase II study.

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,

Product

SL-172154

Abstract

Identification of predictive, treatment-specific Charlson comorbidity score thresholds in acute myeloid leukemia.

Org: VCU Massey Cancer Center, VCU School of Medicine, VCU Department of Internal Medicine, VCU Department of Biostatistics,

Product

trametinib, venetoclax

Abstract

https://www.abstractsonline.com/pp8/#!/10517/presentation/20182